Patents by Inventor Annette Walter

Annette Walter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PIM KINASE INHIBITORS AND METHODS OF THEIR USE
    Publication number: 20140249135
    Abstract: New compounds, compositions and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
    Type: Application
    Filed: May 9, 2014
    Publication date: September 4, 2014
    Applicant: NOVARTIS AG
    Inventors: Matthew Burger, Mika Lindvall, Wooseok Han, Jiong Lan, Gisele Nishiguchi, Cynthia Shafer, Cornelia Bellamacina, Kay Huh, Gordana Atallah, Christopher McBride, William Antonios-McCrea, JR., Tatiana Zavorotinskaya, Annette Walter, Pablo Dominguez Garcia
  • PIM kinase inhibitors and methods of their use
    Patent number: 8822497
    Abstract: New compounds, compositions and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
    Type: Grant
    Filed: March 3, 2008
    Date of Patent: September 2, 2014
    Assignee: Novartis AG
    Inventors: Matthew Burger, Mika Lindvall, Wooseok Han, Jiong Lan, Gisele Nishiguchi, Cynthia Shafer, Cornelia Bellamacina, Kay Huh, Gordana Atallah, Christopher McBride, William Antonios-McCrea, Jr., Tatiana Zavorotinskaya, Annette Walter, Pablo Garcia
  • Substituted imidazole derivates
    Patent number: 8735599
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: May 27, 2014
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Weibo Wang, Paul A. Barsanti, Xia Yia, Rustum S. Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagnition, Ryan N. Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
  • SUBSTITUTED IMIDAZOLE DERIVATIVES
    Publication number: 20130017196
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 17, 2013
    Inventors: Weibo Wang, Paul A. Barsanti, Yia Xia, Rustum Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagnition, Ryan Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
  • Substituted imidazole derivatives
    Patent number: 8318791
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: November 27, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Weibo Wang, Paul A. Barsanti, Yia Xia, Rustum Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagniton, Ryan Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
  • PIM KINASE INHIBITORS AND METHODS OF THEIR USE
    Publication number: 20120208815
    Abstract: New compounds, compositions and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
    Type: Application
    Filed: March 3, 2008
    Publication date: August 16, 2012
    Inventors: Matthew Burger, Mika Lindvall, Wooseok Han, Jiong Lan, Gisele Nishiguchi, Cynthia Shafer, Comelia Bellamacina, Kay Huh, Gordana Atallah, Christopher Mcbride, William Antonios-Mccrea, JR., Tatiana Zavorotinskaya, Annette Walter, Pablo Garcia
  • Substituted imidazole derivatives
    Publication number: 20090258016
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Application
    Filed: June 5, 2009
    Publication date: October 15, 2009
    Inventors: Weibo Wang, Paul A. Barsanti, Yia Xia, Rustum Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagniton, Ryan Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
  • Substituted imidazole derivatives
    Patent number: 7576221
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: August 18, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Weibo Wang, Paul A. Barsanti, Yia Xia, Rustum Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagniton, Ryan Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
  • Substituted 2,5-heterocyclic derivatives
    Patent number: 7470701
    Abstract: The present invention relates to new substituted five-membered compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Grant
    Filed: March 30, 2005
    Date of Patent: December 30, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Xiaodong Lin, Alice Rico, Xiaojing Michael Wang, Yasheen Zhou, Ann B. Jefferson, Annette Walter
  • SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES
    Publication number: 20080255120
    Abstract: The present invention relates to new substituted five-membered compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Application
    Filed: May 29, 2008
    Publication date: October 16, 2008
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Xiaodong Lin, Alice Rico, Xiaojing Michael Wang, Yasheen Zhou, Ann B. Jefferson, Annette Walter
  • INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7
    Publication number: 20070293491
    Abstract: New compounds capable of acting as CDC7 inhibitors are provided. The compounds are useful either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of CDC7 mediated diseases, such as cancer. The compounds have the Formula (I) or (II), where the values of the variables are defined herein.
    Type: Application
    Filed: April 13, 2007
    Publication date: December 20, 2007
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Cynthia Shafer, Annette Walter, Mika Lindvall, Thomas Gesner, Laura Doyle
  • Substituted imidazole compounds as KSP inhibitors
    Publication number: 20070037853
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses of the compounds.
    Type: Application
    Filed: August 9, 2006
    Publication date: February 15, 2007
    Inventors: Paul Barsanti, Yi Xia, Weibo Wang, Kris Mendenhall, Liana Lagniton, Savithri Ramurthy, Megan Phillips, Sharadha Subramanian, Rustum Boyce, Nathan Brammeier, Ryan Constantine, David Duhl, Annette Walter, Tinya Abrams, Paul Renhowe
  • Inhibition of E3-ubiquitin ligase HAKAI for treatment of proliferative disorders
    Publication number: 20060188989
    Abstract: Human HAKAI (hsHAKAI), an E3-ubiquitin ligase, can be inhibited to treat proliferative disorders, such as cancers, dysplasias and hyperplasias. Effective levels of hsHAKAI can be inhibited, for example, using antisense oligonucleotides, ribozymes, interference RNA, and antibodies. Test compounds can be screened for binding to hsHAKAI, for disruption of hsHAKAI-E-cadherin binding, or for inhibition of hsHAKAI enzymatic activity to identify therapeutic compounds for treating proliferative disorders.
    Type: Application
    Filed: April 12, 2006
    Publication date: August 24, 2006
    Applicant: Chiron Corporation
    Inventors: Annette Walter, Christoph Reinhard
  • Cks1 inhibitors
    Publication number: 20060089321
    Abstract: Inhibitors of human Cks1 and human Skp2, including antisense oligonucleotides, methods, and compositions specific for human Cks1 and human Skp2, are provided. Methods of using the compositions for modulating Cks1 expression and Skp2 expression, and for regulating cell growth, particularly tumor cell growth, are also provided.
    Type: Application
    Filed: February 12, 2003
    Publication date: April 27, 2006
    Inventors: Annette Walter, Christoph Reinhard, Anne Jefferson, Blanche-Marie Shamoon
  • Indole and benzimidazole derivatives
    Publication number: 20060084687
    Abstract: The present invention relates to new indole and benzimidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Application
    Filed: October 14, 2005
    Publication date: April 20, 2006
    Inventors: Rustum Boyce, Hongyan Guo, Kris Mendenhall, Annette Walter, Weibo Wang, Yia Xia
  • Substituted imidazole derivatives
    Publication number: 20060009472
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Application
    Filed: June 20, 2005
    Publication date: January 12, 2006
    Inventors: Weibo Wang, Paul Barsanti, Yi Xia, Rustum Boyce, Sabina Pecchi, Nathan Brammeier, Megan Phillips, Kris Mendenhall, Kelly Wayman, Liana Lagniton, Ryan Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul Renhowe, Kenneth Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent Le
  • Substituted 2,5-heterocyclic derivatives
    Publication number: 20050256121
    Abstract: The present invention relates to new substituted five-membered compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Application
    Filed: March 30, 2005
    Publication date: November 17, 2005
    Applicant: Chiron Corporation
    Inventors: Anne Jefferson, Xiaodong Lin, Xiaojing Wang, Alice Rico, Annette Walter, Yasheen Zhou
  • Inhibition of E3-ubiquitin ligase HAKAI for treatment of proliferative disorders
    Publication number: 20050049214
    Abstract: Human HAKAI (hsHAKAI), an E3-ubiquitin ligase, can be inhibited to treat proliferative disorders, such as cancers, dysplasias and hyperplasias. Effective levels of hsHAKAI can be inhibited, for example, using antisense oligonucleotides, ribozymes, interference RNA, and antibodies. Test compounds can be screened for binding to hsHAKAI, for disruption of hsHAKAI-E-cadherin binding, or for inhibition of hsHAKAI enzymatic activity to identify therapeutic compounds for treating proliferative disorders.
    Type: Application
    Filed: January 12, 2004
    Publication date: March 3, 2005
    Applicant: Chiron Corporation
    Inventors: Annette Walter, Christoph Reinhard
  • Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
    Publication number: 20040009156
    Abstract: The present invention is directed toward the use of antisense oligonucleotides that target human kinesin genes for treating diseases involving aberrant cell proliferation, particularly cancers such as colon cancer. Also, the invention is directed to a synergistic combination for treating cancer comprising a chemotherapeutic such as cisplatin and an antisense oligonucleotide that specifically inhibits human kinesin expression.
    Type: Application
    Filed: October 10, 2002
    Publication date: January 15, 2004
    Inventors: Christoph Reinhard, Annette Walter